Fabrication and Evaluation of Voriconazole Loaded Transethosomal Gel for Enhanced Antifungal and Antileishmanial Activity.
fungal infection
leishmaniasis
phospholipids
transethosomal gel
transethosomes
voriconazole
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
23 May 2022
23 May 2022
Historique:
received:
28
03
2022
revised:
11
05
2022
accepted:
18
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
Voriconazole (VRC) is a broad-spectrum antifungal agent belonging to BCS class II (biopharmaceutical classification system). Despite many efforts to enhance its solubility, this primary issue still remains challenging for formulation scientists. Transethosomes (TELs) are one of the potential innovative nano-carriers for improving the solubility and permeation of poorly soluble and permeable drugs. We herein report voriconazole-loaded transethosomes (VRCT) fabricated by the cold method and followed by their incorporation into carbopol 940 as a gel. The prepared VRCT were evaluated for % yield, % entrapment efficiency (EE), surface morphology, possible chemical interaction, particle size, zeta potential, and polydispersity index (PDI). The optimized formulation had a particle size of 228.2 nm, a zeta potential of -26.5 mV, and a PDI of 0.45 with enhanced % EE. Rheology, spreadability, extrudability, in vitro release, skin permeation, molecular docking, antifungal, and antileishmanial activity were also assessed for VRCT and VRC loaded transethosomal gel (VTEG). Ex-vivo permeation using rat skin depicted a transdermal flux of 22.8 µg/cm
Identifiants
pubmed: 35630825
pii: molecules27103347
doi: 10.3390/molecules27103347
pmc: PMC9144605
pii:
doi:
Substances chimiques
Antifungal Agents
0
Antiprotozoal Agents
0
Drug Carriers
0
Voriconazole
JFU09I87TR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : AlMaarefa University
ID : TUMA-2021-22
Références
Eur J Pharm Sci. 2019 Aug 1;136:104956
pubmed: 31202895
Nat Rev Dis Primers. 2018 May 11;4:18026
pubmed: 29749387
Eur J Pharm Biopharm. 2016 Nov;108:253-261
pubmed: 27519827
Drug Deliv. 2016 Sep;23(7):2471-2481
pubmed: 25715807
Methods Mol Biol. 2018;1682:73-88
pubmed: 29039095
Periodontol 2000. 2019 Jun;80(1):148-176
pubmed: 31090135
Eur J Pharm Sci. 2017 Mar 1;99:240-245
pubmed: 28039091
Int J Pharm. 2013 Feb 25;443(1-2):26-38
pubmed: 23313344
Int J Pharm. 2011 Oct 10;418(1):13-7
pubmed: 21034800
Int J Pharm. 2008 Nov 19;364(1):135-41
pubmed: 18778760
AAPS PharmSciTech. 2018 Jul;19(5):2077-2086
pubmed: 29691753
Nano Rev Exp. 2017 Jun 07;8(1):1325708
pubmed: 30410704
AAPS PharmSciTech. 2017 Feb;18(1):58-71
pubmed: 26868380
NanoImpact. 2021 Apr;22:100317
pubmed: 35559974
AAPS PharmSciTech. 2019 Dec 19;21(1):31
pubmed: 31858305
F1000Res. 2017 May 26;6:750
pubmed: 28649370
Eur J Pharm Biopharm. 2016 May;102:101-14
pubmed: 26925505
J Liposome Res. 2018 Mar;28(1):14-21
pubmed: 27667097
Colloids Surf B Biointerfaces. 2019 May 1;177:274-281
pubmed: 30763792
Nat Rev Nephrol. 2020 Jan;16(1):32-50
pubmed: 31399725
Drug Des Devel Ther. 2018 Apr 09;12:795-813
pubmed: 29670336
Expert Opin Drug Deliv. 2010 Apr;7(4):429-44
pubmed: 20331353
Colloids Surf B Biointerfaces. 2012 Apr 1;92:293-8
pubmed: 22221454
Int J Anal Chem. 2020 Mar 13;2020:6129132
pubmed: 32231701
Colloids Surf B Biointerfaces. 2021 Apr;200:111526
pubmed: 33517153
Int J Nanomedicine. 2019 Mar 15;14:1953-1968
pubmed: 30936696
Chem Phys Lipids. 2006 Apr;140(1-2):88-97
pubmed: 16529734
J Infect Dis. 2017 Aug 15;216(suppl_3):S452-S457
pubmed: 28911047
Pharm Res. 2011 Jul;28(7):1683-95
pubmed: 21437791
Drug Dev Ind Pharm. 2020 May;46(5):751-761
pubmed: 32250181
Eur J Pharm Sci. 2016 Dec 1;95:88-95
pubmed: 27600819
Adv Drug Deliv Rev. 2001 Jun 11;48(2-3):137-8
pubmed: 11369078